KALV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KALV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-13), KalVista Pharmaceuticals's share price is $12.25. KalVista Pharmaceuticals's Book Value per Share for the quarter that ended in Jan. 2025 was $2.94. Hence, KalVista Pharmaceuticals's PB Ratio of today is 4.17.
The historical rank and industry rank for KalVista Pharmaceuticals's PB Ratio or its related term are showing as below:
During the past 13 years, KalVista Pharmaceuticals's highest PB Ratio was 13.10. The lowest was 0.29. And the median was 3.12.
During the past 12 months, KalVista Pharmaceuticals's average Book Value Per Share Growth Rate was 14.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -22.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -2.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of KalVista Pharmaceuticals was 61.00% per year. The lowest was -22.70% per year. And the median was 11.85% per year.
The historical data trend for KalVista Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KalVista Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Apr15 | Apr16 | Apr17 | Apr18 | Apr19 | Apr20 | Apr21 | Apr22 | Apr23 | Apr24 | |||||||||||
PB Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
2.32 | 2.37 | 1.69 | 1.81 | 2.34 |
KalVista Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | Apr24 | Jul24 | Oct24 | Jan25 | |
PB Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
6.16 | 2.34 | 3.63 | 3.32 | 3.03 |
For the Biotechnology subindustry, KalVista Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where KalVista Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
KalVista Pharmaceuticals's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Jan. 2025) |
= | 12.25 | / | 2.937 | |
= | 4.17 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
KalVista Pharmaceuticals (NAS:KALV) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of KalVista Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Venrock Healthcare Capital Partners Iii, L.p. | 10 percent owner | 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036 |
Benjamin L Palleiko | officer: CFO and Secretary | C/O KALVISTA PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLD 200, STE 2203, CAMBRIDGE MA 02139 |
Paul K. Audhya | officer: Chief Medical Officer | C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142 |
Christopher Yea | officer: Chief Development Officer | ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139 |
Edward P. Feener | officer: Chief Scientific Officer | ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139 |
Thomas Andrew Crockett | director, officer: President and CEO | BUILDING 227, TETRICUS SCIENCE PARK, PORTON DOWN, SALISBURY, WILTSHIRE X0 SP4 0JQ |
Albert Cha | director | 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
Patrick Treanor | director | C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142 |
Michael David Smith | officer: Senior VP, Development | C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142 |
Andreas Maetzel | officer: Senior Vice President Medical | 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Nancy Stuart | director | 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421 |
Brian Jg Pereira | director | C/O ADVANCED MAGNETICS, INC., 61 MOONEY STREET, CAMBRIDGE MA 02138 |
Daniel B Soland | director | 4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608 |
Martin Edwards | director | 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Sv Life Sciences Fund Iv (gp), L.p. | 10 percent owner | ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108 |
From GuruFocus
By Business Wire • 09-26-2024
By Business Wire • 11-04-2024
By Business Wire • 09-04-2024
By Business Wire • 12-05-2024
By Business Wire • 10-02-2024
By Business Wire • 09-03-2024
By GuruFocus News • 11-05-2024
By Business Wire • 12-16-2024
By Business Wire • 09-30-2024
By Business Wire • 10-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.